New combo aims to free CML patients from daily pills
NCT ID NCT03610971
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether adding ruxolitinib to a standard tyrosine kinase inhibitor (TKI) can help people with chronic myeloid leukemia (CML) stop their medication for longer. Participants had previously tried stopping a TKI but relapsed. The study enrolls 24 adults and measures how many remain in remission without treatment after one year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ruxolitinib (Jakafi) plus a tyrosine kinase inhibitor (imatinib, dasatinib, nilotinib, or bosutinib)
What this could lead to
If successful, this could help some CML patients stay off daily medication for longer periods, reducing side effects and treatment burden.
What could go wrong
This is a small, early-phase study with only 24 participants. The combination may cause more side effects, and not everyone may achieve treatment-free remission.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC PHASE CHRONIC MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
David H. Koch Center for Cancer Care at Memorial Sloan Kettering
New York, New York, 10021, United States
-
Duke University Hospital
Durham, North Carolina, 27710, United States
-
Emory -Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
Froedtert Hospital & the Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
-
Memorial Sloan Kettering - Bergen
Montvale, New Jersey, 07645, United States
-
Oregon Health & Science University
Portland, Oregon, 97239, United States
-
Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14263, United States